Chennai Meenakshi Multispeciality Hospital Ltd vs Dr Lal Pathlabs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 36.4 as of 23 Oct 15:30 . The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Dr Lal Pathlabs Ltd changed from 77.4 on March 2021 to 43.6 on March 2026 . This represents a CAGR of -9.12% over 6 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Dr Lal Pathlabs Ltd changed from ₹ 22565 crore on March 2021 to ₹ 22015 crore on March 2026 . This represents a CAGR of -0.41% over 6 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 829.6 crore as compare to the Mar '26 revenue of ₹ 726.7 crore. This represent the growth of 14.16% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 279.4 crore as compare to the Mar '26 ebitda of ₹ 210.8 crore. This represent the growth of 32.54% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Dr Lal Pathlabs Ltd changed from ₹ 107.8 crore to ₹ 170.5 crore over 9 quarters. This represents a CAGR of 22.60% The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Dr Lal Pathlabs Ltd changed from 59.51 % on March 2021 to 67.59 % on March 2026 . This represents a CAGR of 2.14% over 6 years .

About Chennai Meenakshi Multispeciality Hospital Ltd

Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology. The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.

About Dr Lal Pathlabs Ltd

Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi.
The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company.
The Company converted into a Public Limited Company and name of the Company was changed to Dr. Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015. Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres.
Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations.

FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lal Pathlabs Ltd

Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or Dr Lal Pathlabs Ltd?

Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 27 Cr while Market cap of Dr Lal Pathlabs Ltd is 30,977 Cr

What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lal Pathlabs Ltd?

The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lal Pathlabs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lal Pathlabs Ltd?

As of October 25, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹36.4. On the other hand, Dr Lal Pathlabs Ltd stock price is INR ₹1845.55.

How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lal Pathlabs Ltd compare?

To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lal Pathlabs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.